You just read:

Cellular Biomedicine Group's AlloJoin® Therapy for Knee Osteoarthritis (KOA) Becomes the First Stem Cell Drug Application Approved in China for Phase II Clinical Trials

News provided by

Cellular Biomedicine Group

Jan 17, 2019, 06:00 ET